# Phase 2 Lymphoma, Non-Hodgkin trials recruiting: 52 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials in phase 2 for Lymphoma, Non-Hodgkin that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lymphoma, Non-Hodgkin trials: 52 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lymphoma-non-hodgkin

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 52
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 18, 2026 | NCT07771361 | BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma | Luminary Therapeutics | Phase 2 | Not yet recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771361) |
| August 13, 2026 | NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Recruiting | Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell... | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763210) |
| July 20, 2026 | NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Kure Cells, INC | Phase 2 | Not yet recruiting | Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell... | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713459) |
| June 5, 2026 | NCT07628738 | A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete... | Ruijin Hospital | Phase 2 | Recruiting | Lymphoma (Non-Hodgkin's Lymphoma) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628738) |
| May 15, 2026 | NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588698) |
| May 6, 2026 | NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL | Miltenyi Biomedicine GmbH | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569965) |
| May 5, 2026 | NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566377) |
| December 16, 2025 | NCT07283822 | Amping up With PemJAK | Sponsor not shown (see the record) | Phase 2 | Recruiting | Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent... | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283822) |
| September 29, 2025 | NCT07195799 | Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Non-Hodgkin Lymphoma | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195799) |
| April 8, 2025 | NCT06915246 | A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma | VIVUS LLC | Phase 2 | Recruiting | Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06915246) |
| March 3, 2025 | NCT06854653 | A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Prescient Therapeutics, Ltd. | Phase 2 | Recruiting | CTCL | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06854653) |
| February 3, 2025 | NCT06806033 | Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | Hoffmann-La Roche | Phase 2 | Recruiting | Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06806033) |
| October 17, 2024 | NCT06646211 | High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) | Sun Yat-sen University | Phase 2 | Not yet recruiting | Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06646211) |
| August 30, 2024 | NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | University of California, Irvine | Phase 2 | Recruiting | Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06580002) |
| August 21, 2024 | NCT06563596 | Epco, Zanu, Ritux for R/R FL or MZL | Sponsor not shown (see the record) | Phase 2 | Recruiting | Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06563596) |
| August 12, 2024 | NCT06550141 | Emapalumab Prevention of CAR-T Cell Associated Toxicities | Sponsor not shown (see the record) | Phase 2 | Recruiting | Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma... | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06550141) |
| August 2, 2024 | NCT06534437 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | Ryvu Therapeutics SA | Phase 2 | Recruiting | Non-Hodgkin Lymphoma, B-cell | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06534437) |
| July 30, 2024 | NCT06526793 | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | AstraZeneca | Phase 2 | Recruiting | B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06526793) |
| July 19, 2024 | NCT06510361 | A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With... | Beth Israel Deaconess Medical Center | Phase 2 | Recruiting | Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06510361) |
| July 3, 2024 | NCT06486051 | A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma | Malaghan Institute of Medical Research | Phase 2 | Recruiting | Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06486051) |
| June 28, 2024 | NCT06479356 | CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 | Recruiting | Non-Hodgkin Lymphoma, Large B-cell Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06479356) |
| June 17, 2024 | NCT06462248 | Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies | Sponsor not shown (see the record) | Phase 2 | Recruiting | Lymphoma, Nonhodgkin, Leukemia, Lymphocytic | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06462248) |
| June 13, 2024 | NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | Abramson Cancer Center at Penn Medicine | Phase 2 | Recruiting | Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade... | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06458439) |
| May 23, 2024 | NCT06427213 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | Henan Cancer Hospital | Phase 2 | Not yet recruiting | Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06427213) |
| December 6, 2023 | NCT06158386 | Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06158386) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 3 |
| Canadian Cancer Trials Group | 2 |
| National Cancer Institute (NCI) | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| M.D. Anderson Cancer Center | 2 |
| New York Medical College | 2 |
| Ryvu Therapeutics SA | 1 |
| Kure Cells, INC | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| The First Affiliated Hospital of Xiamen University | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| University of Birmingham | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| City of Hope Medical Center | 1 |
| Shanghai Ming Ju Biotechnology Co., Ltd. | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Prescient Therapeutics, Ltd. | 1 |
| University of California, Irvine | 1 |
| Fred Hutchinson Cancer Center | 1 |
| University of Florida | 1 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Juventas Cell Therapy Ltd. | 1 |
| University Hospital, Clermont-Ferrand | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 31 |
| China | 9 |
| France | 7 |
| Canada | 6 |
| Germany | 5 |
| Italy | 5 |
| Spain | 4 |
| United Kingdom | 4 |
| Australia | 4 |
| Poland | 3 |
| South Korea | 3 |
| Brazil | 2 |
| Denmark | 2 |
| Belgium | 2 |
| Czechia | 2 |
| Hungary | 2 |
| Turkey (Türkiye) | 2 |
| Hong Kong | 1 |
| Japan | 1 |
| Sweden | 1 |
| Taiwan | 1 |
| Austria | 1 |
| Croatia | 1 |
| Finland | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Mediators in the United States](https://specstream.ai/data/businesses/mediators/united-states)
- [Pathology practices in the United States](https://specstream.ai/data/businesses/pathology-practices/united-states)
- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Spices wholesalers in the United States](https://specstream.ai/data/businesses/spices-wholesalers/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
